Drugs / JR-446
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07640984 | Jun 2026 → Jun 2028 expected | mucopolysaccharidosis type 3B | JCR Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06488924 | Nov 2024 → Apr 2030 expected | mucopolysaccharidosis type 3B | JCR Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JR-446 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06488924 ↗ |
| Route | Intravenous | “IV infusion” NCT06488924 ↗ |